TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an announcement.
Recce Pharmaceuticals Ltd. announced the passing of its founder, Dr. Graham JH Melrose, a pioneer in polymer chemistry and infectious diseases. His leadership and vision were instrumental in establishing Recce as a notable player in the biotech industry, focusing on innovative solutions to antibiotic resistance. Dr. Melrose’s legacy continues to inspire the company’s mission and future innovations.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. operates in the biotech industry, focusing on developing anti-infective technologies to combat antibiotic resistance. Founded in 2007 by Dr. Graham JH Melrose, the company has established a portfolio of new class anti-infectives, supported by over 40 granted patents across major pharmaceutical markets.
Average Trading Volume: 122,098
Technical Sentiment Signal: Hold
Current Market Cap: A$124.3M
Learn more about RCE stock on TipRanks’ Stock Analysis page.